New data offer further insight into the effects of the first gene-targeted therapy for ALS, three years after its U.S. Food and Drug Administration approval.
When the FDA granted Tofersen, marketed as Qalsody, accelerated approval in April 2023, it opened the door for clinicians and patients to access a therapy designed to target an underlying genetic cause of ALS. The approval marked a significant milestone for a disease with limited treatment options.
Three years after Qalsody was approved for adults with a mutation in the SOD1 gene, new long-term findings offer a more detailed picture of the long-term effects. They also reveal more about what happens when patients start treatment earlier.
Shifting ALS Treatment Expectations
According to a study published in JAMA Neurology, starting Tofersen spinal injections earlier and maintaining treatment was associated with slower disease progression and better survival outcomes in people with SOD1-ALS. Roughly one in four patients who started treatment early experienced measurable improvements in muscle strength and physical function.
In the clinical trial and its follow-up study, researchers tracked 108 adults with a confirmed disease-causing mutation. The data show that patients who started treatment earlier showed less decline in physical function, respiratory health and muscle strength than those who received a placebo or started six months later. The researchers noted that “VALOR/OLE data are consistent with global trial and expanded access programs indicating that tofersen is slowing neurodegeneration and clinical disease progression in patients.”
For decades, ALS treatments have largely focused on managing symptoms and slowing disease progression. But, sustained improvements in physical function have remained uncommon. The new findings mark a significant milestone in ALS research. It shifts what doctors and families may hope to achieve through early treatment intervention.
Earlier Tofersen Treatment Linked To Better Long-Term Outcomes
Patients who started Tofersen earlier experienced less overall deterioration in physical function, breathing capacity and muscle strength. Researchers tracked these outcomes over 148 weeks, or just under three years, using assessments of daily activities, respiratory health and muscle strength.
By the end of the tracking period, patients in the early-treatment group had lost an average of 9.9 points on the ALS Functional Rating Scale-Revised (ALSFRS-R), compared with 13.5 points in the delayed-treatment group.
Breathing capacity also declined less among patients who started treatment earlier, with an average 13.8% decrease compared to 18.1% in the delayed-treatment group.
What Long-Term Data Reveal About Tofersen’s Safety
Of the 108 participants enrolled in the original trial, 104 received at least one dose of Tofersen. Nearly all of those patients reported at least one adverse safety event. However, not every event was considered treatment related.
Some were associated with ALS progression and the repeated lumbar punctures used to administer the drug. The most frequently reported events included a headache, reported by 60.6% of participants, and procedural pain, reported by 59.6%. Falls and back pain affected 47.1% of participants. Other reported ailments included pain in the extremities, joint pain and fatigue.
Serious neurological events occurred in only 8.7% of patients. These included myelitis, inflammation of the spinal cord, and papilledema, or swelling of the optic nerve. Researchers reported that these events were managed with standard care and resolved. Only one case of myelitis and one case of chemical meningitis led to treatment discontinuation.
A Focus On Reaching More Patients With ALS
Qalsody is currently approved to treat only adults with ALS caused by mutations in the SOD1 gene. Since SOD1 mutations account for just 2% of ALS cases, the vast majority of patients with the disease are ineligible for treatment.
The small size of the eligible patient population also makes genetic testing critical. Clinical guidelines published in Annals of Clinical and Translational Neurology recommend offering genetic testing to everyone diagnosed with ALS, regardless of family history.
Researchers are also investigating whether Tofersen could benefit a broader group of patients. A Washington University trial is evaluating the drug in people with other forms of ALS. Meanwhile, Biogen, the drug’s manufacturer, is conducting the Phase 3 ATLAS trial to examine whether starting treatment before symptoms appear could delay disease onset in people with SOD1 mutations.
What Comes Next?
Tofersen marked an important milestone in ALS treatment, but its reach remains limited. SOD1 mutations account for only about 2% of ALS cases, restricting treatment to a small subset of an already rare disease population. For patients who are eligible today, cost presents another barrier.
BioSpace reported a manufacturer-confirmed price of $14,230 per vial. These estimates bring first-year drug costs to roughly $199,000 to $228,000. The total cost of treatment can rise further when patients face separate charges for intrathecal administration, facility fees, anesthesia and imaging. Genetic testing to determine eligibility can add another expense.
While the long-term findings offer encouraging evidence that earlier treatment may help slow ALS progression, questions remain about how widely Tofersen’s benefits can extend. For now, the results represent a meaningful step forward in ALS research, but affordability and eligibility remain significant barriers to treatment.
